AbbVie to acquire Nimble Therapeutics for $200m.

AbbVie, a pharmaceutical company that discovers, develops, and markets medicines, agreed to acquire Nimble Therapeutics, a biotechnology company, for $200m. "Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, Nimble's novel oral therapies will be well-positioned to reach more people living with autoimmune diseases. The talented, passionate and dedicated team at Nimble has made great progress over the past few years and we are pleased that AbbVie has recognized the tremendous potential of our proprietary platform and emerging immunology pipeline," Jigar Patel, Nimble Therapeutics founder and CEO.